BCTXW - BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND | Benzinga
- BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell's next generation breast and prostate cancer immunotherapies
- Data supports further development of BriaCell's next generation personalized immunotherapy platform with potent anti-tumor activity and favorable safety profile
- FDA authorizes Bria-OTS™ Investigational New Drug Application (IND) opening the path to the clinic
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report unprecedented activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies at the 2023 Society for Immunotherapy of Cancer (SITC) annual meeting. These novel immunotherapies have been shown to activate the immune system through multiple mechanisms including adaptive responses of naïve (resting) T cells and innate responses of dendritic cells and natural killer (NK) cells leading to enhanced clinical efficacy and prevention of immune escape.
BriaCell's current lead candidate, Bria-IMT™, has enhanced efficacy in human leucocyte (HLA) matched patients (LINK) and led to the development of Bria-OTS™, an off the shelf personalized immunotherapy providing HAL matched targeting to >99% of the US population.
"We are extremely excited with our findings confirming unprecedented immune system responses to our novel next generation breast and prostate cancer immunotherapies - designed with additional immune activating components for superior efficacy," stated Dr. William V. Williams, BriaCell's President & CEO. "We expect our novel immunotherapies to boost the immune system in cancer patients leading to tumor destruction. We believe that our technology represents a significant advancement in the field of oncology and personalized immunotherapy."
BriaCell's poster presentation highlights the development details and activities of BriaCell's next generation off-the-shelf personalized immunotherapies for breast and prostate cancers.
Abstract Title: Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors
Abstract Number: 419
Location: San Diego Convention Center, San Diego, CA
Session Date and Time: Friday November 3, 2023 9:00 AM - 6:00 PM
Immune system activation by BriaCell's next generation personalized off-the-shelf immunotherapy
BriaCell has developed next generation, cell-based, personalized immunotherapies, Bria-OTS+™ (for breast cancer) and Bria-PROS+™ (for prostate cancer) that produce immune system activating molecules e.g., antigen presenting cell components and granulocyte macrophage colony stimulating factor (GM-CSF), as well as newly added immune system activating factors such as costimulatory molecules and cytokines.
Potential advantages of BriaCell's next generation personalized off-the-shelf immunotherapies include:
- Precision Therapy: Bria-OTS+™ cell lines are ...